130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
4 citations
,
July 2025 in “International Journal of Molecular Sciences” Targeting amphiregulin may improve treatment for fibrosis and cancer.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”